echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > LEUKEMIA: Complete diagnostic criteria for bone marrow mastocytosis-Proposal of the European Mastocytosis Competence Network

    LEUKEMIA: Complete diagnostic criteria for bone marrow mastocytosis-Proposal of the European Mastocytosis Competence Network

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Mastocytosis is a hematopoietic tumor characterized by the expansion and accumulation of tumor mast cells (MCs) in one or more organ systems , including bone marrow (BM), skin, liver, spleen, and gastrointestinal (GI) ) Channel
    .


    In most patients with systemic mastocytosis (SM), activating mutations of KIT gene (mainly D816V) are detected in tumor cells


    Mastocytosis is a kind of hematopoietic tumor, which is characterized by the expansion and accumulation of tumor mast cells (MCs) in one or more organ systems , including bone marrow (BM), skin, tumor mast cells (MCs) in one or Expansion and accumulation in multiple organ systems The expansion and accumulation of tumor mast cells (MCs) in one or more organ systems includes bone marrow (BM), skin, liver, spleen, and gastrointestinal (GI) channels


    Foreign research teams have conducted a deeper understanding of the poor prognostic factors of WHO-based BMM patients in the ECNM registry data set, and compared whether BMM has these risk factors and the characteristics and characteristics of typical ISM with skin lesions (ISMtyp).
    Ending
    .


    The specific purpose of the research is to improve and update the diagnostic criteria for true BMM


    Foreign research teams have conducted a deeper understanding of the poor prognostic factors of WHO-based BMM patients in the ECNM registry data set, and compared whether BMM has these risk factors and the characteristics and characteristics of typical ISM with skin lesions (ISMtyp).


    In the registered data set of the European Competence Network, they compared the characteristics and outcomes of 390 BMM patients with 1175 typical ISM patients


    These data support the recommendation to define BMM as a separate SM variant, which is characterized by SM criteria, no skin damage, no b-sign, and trypsin level <125 ng/mL


     

    Original source:

    Original source:

    Zanotti, R.


    Zanotti, R.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.